SRTA

#2940
Strata Critical Medical, Inc. - Class A Common Stock
5.3 7 USD
-0.05%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
5.37
5.37
Intervallo Annuale
3.85
6.50
Variazione giornaliera
-5.12%
Variazione Mensile
+6.34%
Variazione di 6 mesi
+9.59%
Variazione Annuale
+27.25%
Chiusura Precedente
5.6 6
Open
5.3 7
Minimo
5.3 7
Massimo
5.3 7
Volume
53
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Strata Critical Medical, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Strata Critical Medical, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Strata Critical Medical, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Strata Critical Medical, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Strata Critical Medical, Inc. current report, Q1 FY2026
8-K

2025

Annual report, FY2025
Strata Critical Medical, Inc. annual report, FY2025
10-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Strata Critical Medical, Inc. current report, Q4 FY2025
8-K

Strata Critical Medical, Inc. current report, Q1 FY2023

Full document

Business Context and Reporting Period

This Form 8-K was filed by Blade Air Mobility, Inc. (not Strata Critical Medical, Inc.) on February 27, 2023, with the earliest event reported on that date. The filing addresses a legal proceeding in the Delaware Court of Chancery regarding the validation of the Company's capitalization and Certificate of Incorporation.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance and legal event rather than financial performance.

Material Changes

There are no financial material changes reported. The significant event is the resolution of a legal uncertainty:

  • The Company previously filed a petition on February 8, 2023, under Section 205 of the Delaware General Corporation Law to resolve uncertainty regarding its capitalization.
  • A hearing was held on February 27, 2023.
  • On February 28, 2023, the Court of Chancery entered an order validating the Company's Second Amended and Restated Certificate of Incorporation as effective from its original filing on May 7, 2021.
  • The Court also validated all securities issued in reliance on the Certificate of Incorporation as of their original issuance dates.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary on future operations. The primary risk addressed was the potential invalidity of the Company's capitalization, which has been resolved by the Court's order. No other contingencies or unusual items are disclosed in this text.

Investor Verification Checklist

  • Verify the ticker symbol BLDE and BLDEW on The Nasdaq Stock Market.
  • Confirm the effective date of the validated Certificate of Incorporation is May 7, 2021.
  • Review the specific details of the "recent Court of Chancery ruling" mentioned as the catalyst for the petition to understand the initial uncertainty.
  • Note that the filing is signed by William A. Heyburn, Chief Financial Officer, on February 28, 2023.